For patients with acute and chronic graft-vs-host disease (GVHD), systemic treatment with steroids is the standard of care, and although steroid-related complications are common, the associated health care resource utilization and costs are not well documented.
A significant proportion of patients receiving steroids for graft-vs-host disease (GVHD) experience complications, adding to both the morbidity and cost of managing GVHD, a common complication of hematopoietic cell transplantation, according to new research presented at the annual meeting of the Academy of Managed Care Pharmacy.
For patients with acute and chronic GVHD, systemic treatment with steroids is the standard of care, and although steroid-related complications are common, the associated health care resource utilization and costs are not well documented.
The study followed nearly 700 patients who were taking steroids for GVHD for a median of 126 days, nearly all (97%) of whom had at least 1 complication. Among these patients, the costs associated with steroid-related complications were higher for those with prolonged steroid use and with acute GVHD. According to the authors, infection was the most common complication throughout the study period and was associated with the highest risk of hospitalization.
Other complications including bone/muscle, gastrointestinal (GI), and metabolic/endocrine complications were documented.
“Most of the steroid-related health care costs in those with complications occurred in the first year of steroid use (94% of 2-year GI costs occurred in the first year, 81% of metabolic/endocrine, 79% of infections, 77% of bone/muscle),” wrote the abstract authors. “Steroid complication‒related health care costs were greatest among patients with an infection, and hospitalizations contributed most to the costs.”
Hospitalizations resulted in a median of $140,637 throughout the 2 years of follow-up, reflecting most of the median $164,787 associated with steroid complication-related costs.
Hospital stays related to steroid complications lasted a median of approximately 20 days and were common, occurring in 26% to 72% of the patients who experienced a complication. The length of hospital stay was similar across all complication types.
The authors of the abstract noted several limitations of their research, including that health care resource utilization and costs associated with steroid-related complications were determined by International Classification of Diseases coding, which was not validated with medical records. The analysis also included only complications that resulted in resource utilization documented in medical claims.
Reference
Bell E, Yu J, Bhatt V, et al. Healthcare resource utilization of steroid-associated complications in patients with graft-versus-host disease. Presented at: Academy of Managed Care Pharmacy 2021; April 12-16, 2021. Abstract D22.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More